Press release
SI-BONE Announces Preliminary Revenue for the Fourth Quarter and Full Year 2024
Fourth Quarter 2024 worldwide revenue of ~$48.8 to $49.0 million representing growth of ~26%Achieved adjusted EBITDA profitability in the fourth quarter SANTA
About this update from Si-bone, Inc.
[{"type":"text","content":"Fourth Quarter 2024 worldwide revenue of ~$48.8 to $49.0 million representing growth of ~26%Achieved adjusted EBITDA profitability in the fourth quarter SANTA CLARA, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced its preliminary and unaudited revenue and cash and cash equivalents for fourth quarter and full year 2024. Fourth Quarter 2024 Summary (any comparisons are to the prior year period) Worldwide revenue between $48.8 - $49.0 million, representing ~26% growthU.S. revenue between $46.7 - $46.9 million, representing ~28% growthEnded the quarter with ~1,390 active physicians in the U.S., representing ~23% growthCash and marketable securities of ~$150 million, implying net cash use of ~$0.8 million in the quarter Fiscal Year 2024 Summary (any comparisons are to the prior year period) Worldwide revenue between $167.0 - $167.1 million, representing ~20% growthU.S. revenue between $158.2 - $158.4 million, representing ~21% growth The fourth quarter and full year 2024 revenue, adjusted EBITDA, and cash and marketable securities are included in this release on a preliminary basis, prior to the completion of SI-BONE's financial closing procedures and audit procedures by its external auditors and therefore may be subject to adjustment. SI-BONE expects to provide fourth quarter and full year 2024 financial results during its fourth quarter 2024 earnings call in late February 2025. About SI-BONE, Inc. SI-BONE (NASDAQ: SIBN) is a global leader in developing unique technologies for surgical treatment of sacropelvic disorders. Since pioneering minimally invasive SI joint surgery in 2009, SI-BONE has supported over 4,300 physicians in performing a total of over 115,000 procedures. A unique body of clinical evidence supports the use of SI-BONE’s technologies, including two randomized controlled trials and over 160 peer reviewed publications. SI-BONE has leveraged its leadership in minimally invasive SI joint fusion to commercialize novel solutions for adjacent markets, including adult deformity, sacropelvic fixation and pelvic trauma. For additional information on the company or the products including risks and benefits, please visit www.si-bone.com. SI-BONE is a registered trademark of SI-BONE, Inc. ©2025 SI-BONE, Inc. All Rights Re...